Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 22.62% and Operating profit at -2.36% over the last 5 years
2
With a growth in Net Sales of 26.33%, the company declared Very Positive results in Sep 25
3
With ROE of 5.73%, it has a fair valuation with a 3.85 Price to Book Value
4
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CNY 6,344 Million (Mid Cap)
67.00
NA
0.00%
-0.68
6.54%
2.40
Revenue and Profits:
Net Sales:
236 Million
(Quarterly Results - Mar 2026)
Net Profit:
46 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-23.35%
0%
-23.35%
6 Months
-20.36%
0%
-20.36%
1 Year
7.45%
0%
7.45%
2 Years
31.54%
0%
31.54%
3 Years
-53.89%
0%
-53.89%
4 Years
-61.68%
0%
-61.68%
5 Years
0%
0%
0.0%
ACROBiosystems Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
22.62%
EBIT Growth (5y)
-2.36%
EBIT to Interest (avg)
48.47
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.66
Sales to Capital Employed (avg)
0.23
Tax Ratio
4.17%
Dividend Payout Ratio
48.37%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
20.75%
ROE (avg)
6.17%
Valuation key factors
Factor
Value
P/E Ratio
67
Industry P/E
Price to Book Value
3.85
EV to EBIT
94.66
EV to EBITDA
48.03
EV to Capital Employed
9.64
EV to Sales
11.37
PEG Ratio
2.13
Dividend Yield
NA
ROCE (Latest)
10.19%
ROE (Latest)
5.73%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
235.60
186.50
26.33%
Operating Profit (PBDIT) excl Other Income
44.40
54.60
-18.68%
Interest
0.40
2.10
-80.95%
Exceptional Items
-0.50
0.00
Consolidate Net Profit
46.30
40.30
14.89%
Operating Profit Margin (Excl OI)
188.70%
172.60%
1.61%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 26.33% vs 27.74% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 14.89% vs 38.01% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
644.10
543.00
18.62%
Operating Profit (PBDIT) excl Other Income
131.00
136.90
-4.31%
Interest
5.70
4.50
26.67%
Exceptional Items
-0.00
0.70
-100.00%
Consolidate Net Profit
120.00
147.60
-18.70%
Operating Profit Margin (Excl OI)
91.20%
142.60%
-5.14%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 18.62% vs 14.61% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -18.70% vs -25.90% in Dec 2023
About ACROBiosystems Co., Ltd. 
ACROBiosystems Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






